Last reviewed · How we verify

NCT01159119: EUR-1066

A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain

Terminated Phase 1 Last updated 18 January 2020
What this trial tests

Phase 1 trial testing EUR-1066-A in Chronic Pancreatitis in 15 participants. Terminated before completion.

Timeline
2 August 2010
Primary endpoint
1 July 2011
1 July 2011

Quick facts

Lead sponsorForest Laboratories
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment15
Start date2 August 2010
Primary completion1 July 2011
Estimated completion1 July 2011
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Forest Laboratories — full company profile →

Who can join

18 and older, any sex, with Chronic Pancreatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate two different treatments in subjects with chronic pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Pancreatitis

Currently open trials in the same condition.

Other Forest Laboratories trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01159119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing